当前位置: 首页 > 期刊 > 《中外医疗》 > 202030
编号:13796552
视神经脊髓炎谱系疾病(4)
http://www.100md.com 2020年10月25日 《中外医疗》 202030
     [14] Ichiro Nakashima,Tetsuya Akai shi.Autoantibodies in Nenromyelitis optica Spectrum Disorders[J].Brain Nerve,2018,70(4):297-304.

    [15] 韩露,李梅,朱德生,等.B淋巴细胞在视神经脊髓炎谱系疾病发病中的作用[J].上海交通大学学报:医学版,2018, 38(1):112-116.

    [16] Mealy MA, Wingerchuk DM, Palace J,et al. Comparison of relapse and treatment failure rates among patients with neur omyelitis optica: multicenter study of treatment efficacy[J].JAMA Neurol,2014,71:324-330.

    [17] Weinshenker BG. What is the optimal sequence of rescue treatments for attacks of neuromyelitis optica spectrum disorder[J].Ann Neurol,2016,79:204-205.

    [18] 杨春生,张秋侠,张璘洁,等.视神经脊髓炎谱系疾病免疫治疗的研究进展[J].中华全科医师杂志,2019,18(5):488-491.

    [19] Tallantyre EC, Whittam DH, Jolles S,et al. Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation[J].Neurol ,2018,265:1115-122.

    [20] 孫庆利,孙阿萍,郑梅,等.视神经脊髓炎谱系病患者疼痛的初步研究[J].中国神经免疫学和神经病学杂志,2017,24(6):381-384.

    (收稿日期:2020-07-22), http://www.100md.com(刘莎 钱伟东)
上一页1 2 3 4